LB Pharmaceuticals is a clinical-stage biopharmaceutical company advancing LB-102 for neuropsychiatric disorders, including schizophrenia and bipolar depression. The company raised over $300 million net proceeds from its September 2025 IPO, resulting in cash, cash equivalents, and marketable securities of approximately $295 million at year-end 2025. Despite ongoing net losses driven by research and development expenses related to LB-102’s clinical programs, the strong liquidity supports continued trial activities. Governance includes comprehensive cybersecurity oversight. No product revenues have been generated to date, and capital allocation prioritizes clinical advancement without dividends or share repurchases planned.